Methotrexate, Prednisolone, and Sulphasalazine Combination Therapy

The combination of methotrexate, prednisolone, and sulphasalazine is a therapeutic regimen used primarily in the treatment of rheumatoid arthritis. This combination therapy has been studied in clinical trials and has shown effectiveness in managing disease activity and slowing radiographic damage in patients with early rheumatoid arthritis. ## Description This combination therapy consists of three medications that work through different mechanisms to reduce inflammation and disease progression in rheumatoid arthritis: 1. **Methotrexate**: A disease-modifying antirheumatic drug (DMARD) that is often the first-line treatment for RA. 2. **Prednisolone**: A corticosteroid that provides rapid anti-inflammatory effects. 3. **Sulphasalazine**: Another DMARD that works through different mechanisms than methotrexate. The COBRA trial (COmbination therapy in early Rheumatoid Arthritis) demonstrated that this combination provided superior disease control compared to sulphasalazine alone, with benefits persisting for up to a year after corticosteroids were discontinued[1]. The typical regimen involves sulphasalazine (2 g/day), methotrexate (7.5 mg/week), and prednisolone (initially at higher doses, then tapered down)[1]. ## Dosing In clinical trials, the dosing regimen typically included: - Sulphasalazine: 2 g/day - Methotrexate: 7.5 mg/week - Prednisolone: Initially 60 mg/day, tapered in 6 weekly steps to 7.5 mg/day[1] ## Efficacy The combination therapy has shown significant benefits in: - Reducing disease activity measures - Slowing radiographic damage progression - Providing better outcomes than monotherapy with sulphasalazine[1][5] In the COBRA trial, at 28 weeks, the radiographic damage score had increased by a median of only 1 in the combined-therapy group compared to 4 in the sulphasalazine monotherapy group[1]. The benefits persisted even after prednisolone was discontinued. ## Side Effects Common side effects may include: - Gastrointestinal issues (nausea, vomiting, upset stomach)[6][8] - Mouth sores[8] - Blood disorders[6][8] - Liver function changes[8] - Fatigue[8] - Headache[6][8] - Hair loss[8] - Dizziness[6][8] When used in combination, there may be an increased risk of gastrointestinal adverse events, especially nausea[6]. ## Development Status This combination therapy has been studied in clinical trials and is used in clinical practice for the treatment of rheumatoid arthritis, particularly in patients with early disease or those who have had an inadequate response to monotherapy.

Other names

COBRA regimen